NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers
18 Years
N/A
Both
Bladder Cancer
Trial Information
NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers
Patients who have been previously treated for bladder cancer and are at a high risk for
recurrence are being monitored for recurrence every 3 months with urine cytology and
cystoscopy as part of standard care.The NMP22 Bladder Cancer ® Test Kit has been designed to
provide an alternative to regular urine cytology. A urine sample will be provided and
divided with a portion being used to assess the NMP22 test kit and the remaining sample to
be sent to the lab for regular urine cytology. Patient charts will be reviewed by a medical
student to record age, clinical stage, pathologic stage, time to disease
progression/recurrence, site of recurrence and survival data.
Inclusion Criteria:
- · History of pTis, pT1, large (>2cm) pTa or multiple pTa bladder cancer tumours.
Written Informed Consent prior to any study-related procedures.
Exclusion Criteria:
- History of bladder cancer tumours other than those listed in inclusion
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Principal Investigator
Jonathan Izawa, MD FRCSC
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Western Ontario, Canada
Authority:
Canada: Ethics Review Committee
Study ID:
R-05-885
NCT ID:
NCT00318266
Start Date:
January 2006
Completion Date:
January 2009
Related Keywords:
- Bladder Cancer
- Detection of Bladder Cancer using NMP22 Urine Test Kit
- Urinary Bladder Neoplasms
Name | Location |
|---|
